Polycystic ovary syndrome: The long-term metabolic risks

Women with polycystic ovary syndrome (PCOS), compared with women without the condition, have a greater chance of developing metabolic syndrome (also known as syndrome X). Recent data have drawn attention to these long-term metabolic risks of PCOS. What is metabolic syndrome, and how can its first-line treatment, metformin, affect my patient’s symptoms of PCOS, including hyperandrogenism, anovulation, infertility, weight loss, and early pregnancy loss?

We address these questions in part 3 of this four-part series, which will continue to be posted on the OBG Management Web site. [ Editor’s note : For readers’ ease of access, all installments of this series will, as they are published, be collected on a single Web page of links.]

Metabolic syndrome

Metabolic syndrome is a cluster of risk factors for cardiovascular disease that, together, increase a woman’s likelihood of a heart attack or stroke (by fourfold compared with those free of the condition) and increase the chance of her developing diabetes mellitus (DM). According to the American Heart Association, between 20% and 25% of the US adult population (between 58 and 73 million men and women) has metabolic syndrome. ¹

The diagnostic criteria for metabolic syndrome are presence of at least three of the following:

• abdominal obesity (excessive fat tissue in and around the abdomen)
• atherogenic dyslipidemia (blood fat disorders—including elevated triglyceride level, low high-density lipoprotein cholesterol [HDL-C] level, and elevated low-density cholesterol [LDL-C] level—that foster arterial plaque buildup)
• elevated blood pressure
• insulin resistance or glucose intolerance
• prothrombotic state (which is a high level of fibrinogen or plasminogen activator inhibitor–1 in the blood)
• proinflammatory state (which is elevated plasma C-reactive protein level).

Metformin

Metformin, a biguanide antidiabetic drug, was first described in the scientific literature in 1957. ² It was first marketed in France in 1979, but it did not receive approval by the US Food and Drug Administration (FDA) for DM until 1994. In contrast to sulfonylurea medications, which work rapidly to control elevated blood glucose levels by increasing pancreatic insulin production, metformin is an insulin-sensitizing agent—it improves peripheral insulin sensitivity and suppresses hepatic gluconeogenesis. Metformin is preferred for initial DM treatment because it does not induce hypoglycemia. Although metformin is not FDA-approved to treat PCOS, it is increasingly being used to treat the syndrome in patients with impaired glucose tolerance and those with no impaired glucose tolerance. More recent research has focused on metformin’s effect on other associated maladies of PCOS, including hirsutism, acne, weight loss, anovulation, pregnancy, and pregnancy loss.

Metformin and hirsutism

PCOS and its associated hyperinsulinemic state causes excess ovarian androgen production and reduces hepatic sex hormone binding globulin (SHBG) production. As treatment with metformin results in lower circulating insulin, the net affect is reduced ovarian androgen production and less free testosterone. Thus, it is reasonable to think metformin would be effective in the treatment of hirsutism. However, conflicting results have been reported with respect to this issue.